SGR Fix by Congress Spawns PAMA; Lab Industry Wary of Law’s Impact
ON APRIL 1, PRESIDENT BARACK OBAMA signed into law the Protecting Access to Medicare Act of 2014 (PAMA). As written, it has the potential to be the most impactful federal legislation on the clinical lab industry since passage of the CLIA 1988 bill.
CEO SUMMARY: Faced with a literal tidal wave of new medical procedures, new therapeutic drugs, and new diagnostic tests, Medicare is crafting a unique strategy. As a new clinical option reaches the market, Medicare will reimburse—but only if the patient participates in a clinical study and these studies are paid for by either vendors or
Wholesale prices for general acute care hospitals has climbed steadily in recent months. As tracked by the U.S. Labor Department’s Wholesale Producer Price Index, hospital prices increased 0.5%. For the 12 months ending in February, hospital prices were up 4.7%. This is almost double the annual rate tracked by the Labor Department in 1999 and
ONE CONSEQUENCE of the terrorist attacks on September 11 is that proposed reforms to Medicare lab reimbursement policies have assumed a lesser priority with the current Congress.
Despite that fact, Congress must still address the day-to-day requirements of managing government functions. Thus, there is still activity under way to develop and pass bills affecting funding and
EACH YEAR IT BECOMES more difficult to make final selections for our annual Movers & Shakers awards. The reason is simple.
Today there are more examples of leadership in the laboratory than when we first started these selections three years ago. This is a good omen. It means that the crucible of the marketplace is forging